ARTICLE | Product Development
NGM pops on additional Phase II NASH data for aldafermin
February 25, 2020 1:03 AM UTC
Positive histology data helped NGM snap a losing streak for NASH therapies and lifted the biotech’s stock on a day where the sector and broader markets saw mostly red.
Shares of NGM Biopharmaceuticals Inc. (NASDAQ:NGM) gained as much as 42% Monday after once-daily aldafermin (NGM282) 1 mg showed a statistically significant improvement on the secondary composite endpoint of fibrosis improvement and resolution of non-alcoholic steatohepatitis, with 22% of aldafermin-treated patients achieving the endpoint vs. 0% of patients in the placebo arm (p<0.05)...